ArticlePilot and feasibility studies2026
Effects of a hybrid online/in-person implementation of the complete health improvement program on biomarkers, biometrics, and drug utilization in type 2 diabetes mellitus: a pilot randomized-controlled trial.
Article in Pilot and feasibility studies, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04924400 (Complete Health Improvement Program to Improve Glycemic Control and Reduce Cost of Care for Geisinger Health Plan Members With Type 2 Diabetes), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Complete Health Improvement Program to Improve Glycemic Control and Reduce Cost of Care for Geisinger Health Plan Members With Type 2 Diabetes
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundRandomized-controlled trials of the Complete Health Improvement Program (CHIP) were conducted before new-generation pharmacotherapies, such as GLP-1 and SGLT2 agents, were available. Other attempts to characterize the impact of CHIP since the advent of modern therapies lacked control groups. A new study is needed to evaluate the impact of CHIP on a population with access to modern pharmacotherapies.
methodsPatients with type 2 diabetes mellitus (T2DM) were enrolled. Patients were randomly assigned to CHIP over 12 weeks in a hybrid online/in-person format plus usual care or usual care alone, which consisted of access to standard Geisinger Health Plan diabetes-related services. Feasibility measures included recruitment, retention and participation rates. Clinical efficacy outcomes included change in HbA1c, weight, waist circumference, lifestyle survey results, and diabetes drug utilization by drug class at 3 and 6 months versus baseline.
resultsRecruitment fell short of the targeted 60 patients (N = 25 enrolled, 13 and 12 patients randomized to the intervention and control groups, respectively). 69% of intervention participants who attended baseline visits completed at least 50% of classes, which was slightly below the target of ≥ 70%. Lifestyle survey participation was low but suggested improvements in nutrition, exercise, and sleep among intervention participants who did complete surveys. At 6 months, change in HbA1c was - 0.46% [95% CI - 0.93, 0.01] and - 0.58% [95% CI - 0.95, - 0.22] for the intervention and control groups, respectively. Patients in the intervention group collectively weaned off insulin therapy vs. escalated insulin therapy in the control group. There was a reduction in waist circumference in the intervention group compared to an increase in the control group (- 4.65 [95% CI - 9.71, 0.41] vs. 0.56 [95% CI - 1.66, 2.78] inches, respectively).
conclusionsLifestyle and clinical data from this pilot clinical trial mostly aligned with previous studies. A larger trial is needed to confirm the benefits of CHIP for body composition, to further characterize the clinical effects of CHIP participation, and to understand interactions between lifestyle intervention and modern T2DM pharmacotherapy. Feasibility issues identified in this pilot study would need to be overcome to accomplish such a trial.
trial registrationThis study was registered with ClinicalTrials.gov on 05/20/2021. REGISTRATION NUMBER: NCT04924400 .
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.